MarketCapExport financials
Predictive Oncology (POAI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Predictive Oncology Income Statement 2025-2001 | POAI
Brief overview of financial results at Predictive Oncology
The overview follows changes across a five-year period. The revenue attributed to Predictive Oncology moved from $1.3 million to $125 thousand between the two endpoints. The five-year change reached −90%, while CAGR stood at −36.9%. The negative rate indicates weakening core operations.
The five-year change in gross profit reached −93.5%: from $805 thousand to $52.7 thousand. Cost of revenue developed less favorably than sales and pressured gross profitability. The gross margin was 64.3% at the start and 42% at the end. A lower margin indicates deterioration in the economics of the core business.
EBITDA changed from −24.9 million dollars to −181 million dollars (−627.2%). The operating result developed less favorably than sales. EBITDA margin moved from −1985.2% to −144301.5%. Cost pressure reduced operating profitability.
The net financial result changed from −$25.9 million to −$233 million. Larger losses indicate rising pressure on the business.
Financial takeaway
The current trajectory does not yet confirm a sustainable recovery. The main areas of concern are pressure on operating profitability, lower net income and weak sales momentum. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Predictive Oncology
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 553 K | 10.2 M | 1.22 M | 48.3 M | 12.4 M | 7.46 M | 13.5 M | 5.47 M | 6.47 M | 12 M | 12 M | 47.4 M | - | - | - | - | - | - | - | - | - | - | - | - |
Shares |
17.4 M | 364 K | 4.01 M | 3.69 M | 54.9 M | 12 M | 2.87 M | 1.28 M | 636 K | 282 K | 15.5 K | 12 K | 10 K | - | - | 14 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
- | 1.52 | 2.55 | 0.33 | 0.881 | 1.04 | 2.45 | 10.9 | 13.6 | 22.5 | 750 | 1.24 K | 4.5 K | 1.56 K | 3.09 K | - | - | - | - | - | - | - | - | - | - |
Net Income |
-233 M | -12.7 M | -14 M | -25.7 M | -19.7 M | -25.9 M | -19.4 M | -10.1 M | -7.75 M | -6.53 M | -4.79 M | -6.83 M | -9.41 M | -7.42 M | -4.49 M | -1.35 M | -2.89 M | -1.76 M | -752 K | -273 K | -124 K | -90.4 K | -90.5 K | -51.1 K | - |
Revenue |
125 K | 84.8 K | 493 K | 1.51 M | 1.42 M | 1.25 M | 1.41 M | 1.41 M | 655 K | 456 K | 654 K | 952 K | 468 K | 189 K | 96.6 K | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
72.6 K | 78.3 K | 195 K | 505 K | 487 K | 447 K | 532 K | 416 K | 148 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 6.53 K | 297 K | 1 M | 934 K | 805 K | 880 K | 996 K | 507 K | 275 K | 350 K | 566 K | 278 K | 60.2 K | 40.6 K | 148 | - | - | - | - | - | - | - | - | - |
Operating Income |
-181 M | -10.3 M | -11.1 M | -26 M | -20.4 M | -25.4 M | -22.6 M | -7.86 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | 3 | 391 K | 378 K | 637 K | 259 K | 230 K | 147 K | - | - | - | - | - | - | - | - | - |
EBITDA |
-181 M | -10.2 M | -10.9 M | -24.7 M | -19.1 M | -24.9 M | -13.1 M | -7.71 M | -7.68 M | -6.44 M | -4.32 M | -6.4 M | -8.78 M | -7.16 M | -4.1 M | 2.43 K | - | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 10.3 M | 11.4 M | 27 M | - | 10.9 M | 14.7 M | 8.86 M | 8.25 M | 6.8 M | 4.75 M | 7.03 M | 9.21 M | 7.22 M | 4.15 M | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
25.9 M | 7.24 M | 7.86 M | 11.1 M | 10.9 M | 10.4 M | 9.78 M | 4.63 M | 7.25 M | 5.17 M | 4.25 M | 5.86 M | 8.63 M | 7.05 M | 3.91 M | 1.87 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Predictive Oncology
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
21.2 M | 724 K | 9.11 M | 7.15 M | 444 K | 426 K | 4.66 M | 4.06 M | 4.06 M | 4.03 M | 4 M | 3.97 M | 3.94 M | 3.92 M | 3.59 M | 3.29 M | 65.6 M | 65.4 M | 51.6 M | 36.5 M | 19.8 M | 15 M | 9.84 M | 4.89 M | 4.06 M | 3.15 M | 2.96 M | 1.57 M | 1.41 M | 1.33 M | 11.9 M | 11.4 M | 6.94 M | 6.23 M | 6.17 M | 6.45 M | 4.56 M | 3.32 M | 2.7 M | 724 K | 208 K | 157 K | 3.26 M | 3.1 M | 3.09 M | 2.98 M | 2.97 M | 2.95 M | 2.93 M | 1.82 M | 121 M | 108 M | 104 M | 79.5 M | 54.7 M | 32.7 M | 32.1 M | 16.6 M | 16.6 M | 32.1 M |
Net Income |
-7.71 M | -77.7 M | -2.07 M | -2.44 M | - | -3.09 M | -3.18 M | -4.22 M | - | -3.16 M | -3.92 M | -3.42 M | - | -4.06 M | -10.4 M | -3.37 M | - | -5.44 M | -2.57 M | -3.89 M | - | -6.31 M | -3.58 M | -4.53 M | - | -4.01 M | 1.47 M | -3.29 M | - | -2.51 M | -2.37 M | -1.76 M | - | -992 K | -2.54 M | -7.75 M | - | -6.53 M | -6.53 M | -6.53 M | - | -4.79 M | -1.19 M | -226 K | - | -1.12 M | -1.74 M | -1.62 M | - | -3.97 M | -1.18 M | -2.1 M | - | -2.86 M | -2.14 M | -713 K | - | -477 K | -477 K | -4.49 M |
Revenue |
35.3 K | 3.62 K | 2.68 K | 110 K | - | 3.91 K | 67.3 K | 4.86 K | - | 677 K | 490 K | 240 K | - | 456 K | 372 K | 315 K | - | 314 K | 350 K | 280 K | - | 481 K | 183 K | 295 K | - | -440 K | -440 K | -440 K | - | -646 K | -961 K | 412 K | - | 153 K | 107 K | 175 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
6.77 K | 8.36 K | 18.2 K | 45.1 K | - | 11.2 K | 13.9 K | 22.4 K | - | 97.9 K | 160 K | 120 K | - | 108 K | 134 K | 109 K | - | 110 K | 143 K | 97.8 K | - | 175 K | 85.3 K | 92.7 K | - | 208 K | 118 K | 73.7 K | - | 83 K | 109 K | 117 K | - | 28.7 K | 22 K | 37 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | -4.74 K | -15.5 K | 65.2 K | - | -7.27 K | 53.4 K | -17.6 K | - | 579 K | 330 K | 120 K | - | 348 K | 238 K | 205 K | - | 203 K | 207 K | 183 K | - | 306 K | 97.5 K | 202 K | - | 315 K | 168 K | 182 K | - | 247 K | 250 K | 294 K | - | 124 K | 84.8 K | 138 K | - | 108 K | 48.7 K | 11 K | - | 66 K | 150 K | 55.3 K | - | 263 K | 220 K | 39.1 K | - | 81.7 K | 83.5 K | 83.5 K | - | -18.3 K | 23.2 K | 8.83 K | - | 9.1 K | 554 | - |
Operating Income |
-7.73 M | -3.28 M | -2.66 M | -2.29 M | - | -2.16 M | -2.46 M | -3.58 M | - | -2.74 M | -3.96 M | -3.46 M | - | -4.13 M | -10.5 M | -3.41 M | - | -5.49 M | -2.6 M | -3.78 M | - | -5.61 M | -3.77 M | -3.44 M | - | -3.44 M | -5.1 M | -2.34 M | - | -1.86 M | -1.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.22 K | - | - | - | - | - | - | - | - | - | - | 3 | - | - | - | 51.8 K | 189 K | 154 K | - | 132 K | 14.8 K | 18.1 K | - | 408 K | 127 K | 95.6 K | - | 23.7 K | 89.3 K | 55.5 K | - | 61 K | 57.9 K | 57.9 K |
EBITDA |
-7.7 M | -3.25 M | -2.63 M | -2.25 M | - | -2.13 M | -2.43 M | -3.55 M | - | -2.7 M | -3.78 M | -3.23 M | - | -3.9 M | -10.3 M | -3.09 M | - | -4.52 M | -1.95 M | -3.46 M | - | -4.89 M | -3.37 M | -3.23 M | - | -2.96 M | -4.84 M | -2.3 M | - | -1.76 M | -1.37 M | 18.2 K | - | 53.8 K | 36 K | 18.6 K | - | 62.4 K | 42.1 K | 21 K | - | 57.5 K | 39 K | 19.9 K | - | 44.1 K | 25.8 K | 9.38 K | - | 156 K | 141 K | 311 | - | 768 | 457 | 147 | - | 1.82 K | 1.21 K | 607 |
Operating Expenses |
- | 3.28 M | 2.64 M | 2.35 M | - | 2.15 M | 2.52 M | 3.56 M | - | 3.32 M | 4.29 M | 3.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.34 M | - | - | - | 1.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
2.91 M | 2.61 M | 1.88 M | 1.83 M | - | 1.55 M | 1.83 M | 2.33 M | - | 2.34 M | 2.7 M | 2.34 M | - | 3.29 M | 2.35 M | 2.42 M | - | 2.06 M | 2.08 M | 3.27 M | - | 2.23 M | 3.21 M | 2.83 M | - | 2.62 M | 3.31 M | 1.5 M | - | 763 K | 730 K | 1.24 M | - | 622 K | 2.21 M | 1.13 M | - | 733 K | 2.26 M | 1.69 M | - | 861 K | 856 K | -128 K | - | 738 K | 1.33 M | 1.18 M | - | 3.2 M | 888 K | 888 K | - | 2.52 M | 1.95 M | 566 K | - | 429 K | 273 K | 313 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Predictive Oncology (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 194.34 | 0.3 % | $ 55.9 B | USA |
 |
Alcon
ALC
|
$ 67.43 | -0.58 % | $ 33.3 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
$ 428.12 | -2.26 % | $ 153 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 2.3 % | $ 144 M | USA |
 |
AtriCure
ATRC
|
$ 57.67 | -0.23 % | $ 2.75 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.31 | -8.31 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 91.4 | 0.24 % | $ 5.41 B | USA |
 |
Nephros
NEPH
|
$ 3.59 | 1.99 % | $ 38.1 M | USA |
 |
electroCore
ECOR
|
$ 7.35 | -1.87 % | $ 62.4 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.19 | 0.96 % | $ 3.9 B | USA |
 |
Baxter International
BAX
|
$ 24.7 | 0.78 % | $ 12.7 B | USA |
 |
Pro-Dex
PDEX
|
$ 60.56 | 1.96 % | $ 195 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.31 | 0.92 % | $ 3.46 B | USA |
 |
Repligen Corporation
RGEN
|
$ 180.01 | 0.63 % | $ 10.1 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.61 | -3.18 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
$ 221.48 | -1.58 % | $ 21.7 B | USA |
 |
Stereotaxis
STXS
|
$ 0.99 | -0.34 % | $ 90 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 14.05 | -1.26 % | $ 290 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 176.85 | 1.97 % | $ 10.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 74.72 | -0.47 % | $ 242 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.89 | 0.68 % | $ 494 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 117.11 | -0.93 % | $ 5.53 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 393.48 | 1.21 % | $ 28.4 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.55 | -0.26 % | $ 3.63 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.67 | 0.32 % | $ 1.89 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.49 | 1.8 % | $ 377 M | USA |
 |
ICU Medical
ICUI
|
$ 160.84 | -0.15 % | $ 3.96 B | USA |
 |
ResMed
RMD
|
$ 246.2 | 0.31 % | $ 35.8 B | USA |
 |
OraSure Technologies
OSUR
|
$ 3.86 | 3.07 % | $ 284 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.08 | 2.37 % | $ 1.81 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 130.4 | -0.57 % | $ 5.82 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
$ 58.97 | -0.25 % | $ 11.7 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.94 | -0.78 % | $ 43 M |  Israel |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |